Fenofibrate

Generic Name
Fenofibrate
Brand Names
Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide
Drug Type
Small Molecule
Chemical Formula
C20H21ClO4
CAS Number
49562-28-9
Unique Ingredient Identifier
U202363UOS
Background

Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.

Fenofibrate was granted FDA approval on 31 December 1993.

Indication

Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.

Associated Conditions
Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia
Associated Therapies
-
Clinical Trials
Related News

A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation

Phase 2
Recruiting
Conditions
Liver Transplant
Interventions
Drug: Fenofibrate
First Posted Date
2022-08-24
Last Posted Date
2024-07-03
Lead Sponsor
Mayo Clinic
Target Recruit Count
148
Registration Number
NCT05514119
Locations
🇺🇸

Mayo Clinic Arizona, Phoenix, Arizona, United States

Cardiovascular, Pulmonary, and Integrative Functional Phenotypes in COVID-19 Survivors - Effect of Fenofibrate

Completed
Conditions
Covid19
Interventions
Drug: Placebo
Drug: Fenofibrate
First Posted Date
2021-10-15
Last Posted Date
2024-06-21
Lead Sponsor
University of Pennsylvania
Target Recruit Count
12
Registration Number
NCT05080192
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

Phase 2
Active, not recruiting
Conditions
Diabetic Nephropathies
Interventions
Drug: Fenofibrate
Other: Placebo
First Posted Date
2021-06-18
Last Posted Date
2024-12-02
Lead Sponsor
Alessandro Doria
Target Recruit Count
40
Registration Number
NCT04929379
Locations
🇺🇸

Joslin Diabetes Center, Boston, Massachusetts, United States

🇺🇸

Lahey Hospital and Medical center, Burlington, Massachusetts, United States

🇺🇸

Brehm Center for Diabetes Research / University of Michigan, Ann Arbor, Michigan, United States

and more 1 locations

Serine and Fenofibrate Study in Patients With MacTel Type 2

Phase 2
Active, not recruiting
Conditions
Macular Telangiectasia Type 2
Interventions
Dietary Supplement: Serine
Drug: Fenofibrate
First Posted Date
2021-05-28
Last Posted Date
2024-03-13
Lead Sponsor
The Lowy Medical Research Institute Limited
Target Recruit Count
60
Registration Number
NCT04907084
Locations
🇺🇸

The Eye Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

🇺🇸

University of Washington, Seattle, Washington, United States

🇺🇸

Emory University, Atlanta, Georgia, United States

and more 6 locations

Effects of Oral Fenofibrate on Retinal Thickness and Macular Volume

First Posted Date
2021-05-13
Last Posted Date
2021-05-13
Lead Sponsor
Indonesia University
Target Recruit Count
36
Registration Number
NCT04885153

Fenofibrate for Prevention of DR Worsening

Phase 3
Recruiting
Conditions
Diabetic Retinopathy
Interventions
Other: Placebo
Drug: Fenofibrate
First Posted Date
2020-12-10
Last Posted Date
2024-08-26
Lead Sponsor
Jaeb Center for Health Research
Target Recruit Count
560
Registration Number
NCT04661358
Locations
🇺🇸

Foundation for Vision Research and Retina Specialists of Michigan, P.C., Grand Rapids, Michigan, United States

🇺🇸

Salehi Retina Institute Inc., Huntington Beach, California, United States

🇺🇸

Pittsburg Clinical Trial Consortium, Sewickley, Pennsylvania, United States

and more 58 locations

Fenofibrate Therapy in Pathological Unconjugated Hyperbilirubinemia in Full Term Infants

Not Applicable
Completed
Conditions
Neonatal Jaundice
Interventions
Drug: Placebo
Drug: Fenofibrate
First Posted Date
2020-06-05
Last Posted Date
2020-06-05
Lead Sponsor
Mansoura University
Registration Number
NCT04418180

Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy

Phase 4
Conditions
Dyslipidemias
Interventions
Drug: Fenofibrate
First Posted Date
2019-03-14
Last Posted Date
2019-03-15
Lead Sponsor
Daewon Pharmaceutical Co., Ltd.
Target Recruit Count
180
Registration Number
NCT03874260
Locations
🇰🇷

Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Korea, Republic of

Effects of Fenofibrate Therapy in Diabetic Nephropathy

First Posted Date
2019-03-11
Last Posted Date
2020-12-14
Lead Sponsor
Singapore General Hospital
Target Recruit Count
300
Registration Number
NCT03869931
Locations
🇸🇬

Singapore General Hospital, Singapore, Singapore

Fenofibrate in Type 2 Diabetes

Phase 4
Completed
Conditions
Diabetes Mellitus, Type II
Interventions
Drug: Fenofibrate
First Posted Date
2019-02-04
Last Posted Date
2023-10-24
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
10
Registration Number
NCT03829514
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy